Biocon Ltd, in the pharma sector, witnessed a 40% decline from the December 2020 high but shows signs of a bullish trend. Traders are recommended to consider buying for target levels of 325-350. The daily Relative Strength Index (RSI) is at 65.0. RSI below 30 is oversold and above 70 is considered overbought, Trendlyne data showed.
Jefferies has downgraded the pharma stock Biocon to 'underperform' from 'hold'. However, Jefferies has maintained its target price of ₹250 for the stock, implying an 11 percent downside from its current market price of ₹281.50.
The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocons stake dilution in Bicara Therapeutics.
Biocon Biologics signed a distribution agreement with Sandoz, granting the company the exclusive rights to promote, sell and distribute Adalimumab BS for subcutaneous injection.
EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. The gross R&D spends grew 10% YoY to Rs 278 crore in Q2FY24.
Biocon Share Price: Find the latest news on Biocon Stock Price. Get all the information on Biocon with historic price charts for NSE / BSE. Experts & Broker view also get the Biocon Ltd. buy/sell tips detailed news, announcements, Forecasts, Analysts, Valuation, Earning forecasts, Estimates, Recommendations, Analysts Ratings, financial report, company information, annual report, balance sheet, profit & loss account, results and more.